Navigation Links
Stiefel Laboratories Appoints First Chief Scientific Officer
Date:4/7/2008

CORAL GABLES, Fla., April 7, 2008 /PRNewswire/ -- Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, today announced Gavin Corcoran, M.D., FACP, has been promoted to the newly created position of chief scientific officer.

Creating the position of chief scientific officer will reinforce the already critical role played by the R&D organization and the unity between all R&D departments. It also will further strengthen the collaboration among Stiefel's five R&D facilities around the world.

As chief scientific officer, Corcoran will oversee global scientific and operational activities related to product development and support; medical and scientific affairs; clinical and pre-clinical research; pharmacovigilance; portfolio planning; and regulatory affairs.

"Gavin's promotion to chief scientific officer is a testament to the wonderful work he has done for Stiefel since he came on board," said Brent Stiefel, executive vice president, Global Corporate Development and Product Portfolio. "We chose Gavin to lead our R&D division because his vast experience along with his keen understanding of the industry arms him with the insight that will improve today's skin treatments and develop tomorrow's solutions."

The accomplishments Stiefel references include Corcoran establishing global R&D headquarters in Research Triangle Park, North Carolina; helping to lead integration following the acquisition of Connetics Corporation; overseeing R&D facilities on four continents; and strengthening the alignment of the R&D objectives and structure with the strategic direction of the business.

Prior to his promotion, Corcoran served as senior vice president, Global Research and Development. He joined Stiefel in 2005 as senior vice president, Global Clinical and Regulatory Affairs and has been a driving force in advancing the expansion of a world-class, global research and development organization. With this promotion, Corcoran will remain in Stiefel's R&D headquarters in Research Triangle Park and continue to report to Brent Stiefel.

Corcoran is a physician with specialties in internal medicine and infectious diseases and professional experience in private practice, academia and the pharmaceutical industry. A native of South Africa, he attended medical school at the University of the Witwatersrand in Johannesburg. His extensive pharmaceutical experience includes clinical research and regulatory leadership positions at Bayer, Schering-Plough and Amgen. In addition, he has successfully worked on drug development in a variety of fields, including anti-infectives, diabetes and dermatological infections.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories (a privately held company) is the world's largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Some of the newest and best- known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%) available in the Duac(R) Care System (CS); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, 0.05% and Olux-E(TM) (clobetasol propionate) Foam, 0.05% also available in the Olux(R) / Olux-E(TM) COMPLETE PACK; Soriatane(R) (acitretin) Capsules available in the Soriatane(R) CK CONVENIENCE KIT; Verdeso(TM) (desonide) Foam, 0.05%; Brevoxyl(R)-4 Creamy Wash (benzoyl peroxide 4%) and Brevoxyl(R)-8 Creamy Wash (benzoyl peroxide 8%) packaged in the Brevoxyl(R) Acne Wash Kit; Extina(R) (ketoconazole) Foam, 2%; Oilatum(R) Cleansing Bar; Physiogel(R); Stieprox(R) (ciclopirox olamine); REVALESKIN(TM); and Sarna(R). Its wholly-owned global network is comprised of more than 30 subsidiaries, manufacturing plants in six countries, research and development facilities on four continents, and products marketed in more than 100 countries around the world.

Stiefel Laboratories supplements its R&D efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel Laboratories, Inc. visit http://www.stiefel.com.


'/>"/>
SOURCE Stiefel Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Stiefel Laboratories, Inc. Appoints New President
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
4. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
6. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
7. Andrew Lessmans TWC Construction and ProCaps Laboratories Contract With DT Solar to Install a 700 kW Solar Electric System
8. Mesa Laboratories Names New Vice President of Sales and Marketing
9. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
10. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
11. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: